The WACC of Living Cell Technologies Ltd (LCT.AX) is 6.1%.
Range | Selected | |
Cost of equity | 5.3% - 10.9% | 8.1% |
Tax rate | 14.0% - 18.7% | 16.35% |
Cost of debt | 5.0% - 5.0% | 5% |
WACC | 4.8% - 7.5% | 6.1% |
Category | Low | High |
Long-term bond rate | 4.1% | 4.6% |
Equity market risk premium | 5.5% | 6.5% |
Adjusted beta | -0.06 | 0.65 |
Additional risk adjustments | 1.5% | 2.0% |
Cost of equity | 5.3% | 10.9% |
Tax rate | 14.0% | 18.7% |
Debt/Equity ratio | 1 | 1 |
Cost of debt | 5.0% | 5.0% |
After-tax WACC | 4.8% | 7.5% |
Selected WACC | 6.1% | |
Debt/Equity | Unlevered | |||
Peers | Company Name | ratio | Beta | beta |
LCT.AX | Living Cell Technologies Ltd | 1.18 | -0.72 | -0.36 |
ACW.AX | Actinogen Medical Ltd | 0 | -0.8 | -0.8 |
ATX.AX | Amplia Therapeutics Ltd | 0 | -0.19 | -0.19 |
BIT.AX | Biotron Ltd | 0 | 2.31 | 2.3 |
CUV.AX | Clinuvel Pharmaceuticals Ltd | 0 | 0.96 | 0.95 |
DXB.AX | Dimerix Ltd | 0 | 2.94 | 2.94 |
KZA.AX | Kazia Therapeutics Ltd | 0.1 | -1.19 | -1.1 |
PYC.AX | PYC Therapeutics Ltd | 0 | 2 | 2 |
SCU.AX | Stemcell United Ltd | 0.19 | -0.63 | -0.54 |
TLX.AX | Telix Pharmaceuticals Ltd | 0.07 | 1.5 | 1.42 |
VBS.AX | Vectus Biosystems Ltd | 0.01 | 0.05 | 0.05 |
Low | High | |
Unlevered beta | -0.19 | 0.95 |
Relevered beta | -0.58 | 0.48 |
Adjusted relevered beta | -0.06 | 0.65 |
The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.
This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.
Here’s how we figure out the cost of equity for LCT.AX:
cost_of_equity (8.10%) = risk_free_rate (4.35%) + equity_risk_premium (6.00%) * adjusted_beta (-0.06) + risk_adjustments (1.75%)
We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.